Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model

Trial Profile

Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs ACE 527 (Primary)
  • Indications Diarrhoea; Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
  • Focus Therapeutic Use
  • Sponsors TD Vaccines A/S
  • Most Recent Events

    • 06 Dec 2010 Results presented in a TD vaccines A/S media release
    • 06 Dec 2010 Status changed from recruiting to completed.
    • 31 Mar 2010 Actual initiation date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top